Koo,

If you like ESPR for their drug ETC-1002, keep an eye on Catabasis (CATB). Here's a recent Seeking Alpha article on Catabasis. They have a phase 2a hypercholesterolemia (LDL-lowering) trial with their drug CAT-2054 with results expected mid-year as well as another phase 2 program for Duchenne muscular dystrophy with results expected late 2016. Similar to ESPR/ETC-1002, Catabasis/CAT-2054 is looking to advance a statin-alternative or statin add-on to lower LDL-cholesterol is statin-intolerant patients.

The niche of Catabasis is on their SMART-linker technology, which links 2 drugs together and renders them more or less inert until the linked molecules are taken up into the cell and the linker is cleaved by an intracellular enzyme. It allows for 2 different drugs, which both alone have beneficial or synergistic effects, to be released at the same time in the same location to elicit effects greater than if the two compounds were given together without the linker.

http://seekingalpha.com/article/3975291-catabasis-pharmaceuticals-buy-novel-hypercholesterolemia-dmd-drug-candidates

Note: This is not investment advice or solicitation to buy or sell any security. Investors should do their own research and consult their financial adviser before making any investment.

BearDownAZ